title: Rituximab in lymphomatoid granulomatosis.
abstract: BACKGROUND
  Lymphomatoid granulomatosis (LG) is an Epstein-Barr virus-associated, multisystemic disease that combines a granulomatous inflammatory process with lymphoproliferative potential. It is a rare disorder with a variable clinical presentation ranging from an indolent process to an aggressive B-cell lymphoma. Outcome is unpredictable, and a standard treatment has not yet been established. Cases treated with rituximab, an anti-CD20 monoclonal antibody, have been reported with variable results.
  
  
  METHODS
  We report on 2 children with LG treated with rituximab and review the literature. The first patient had good response but the second did not.
  
  
  CONCLUSIONS
  Rituximab is a treatment option for LG.
authors: Departments of *Pediatric Hematology-Oncology †Dermatology ‡Radiology §Paediatrics ∥Pathology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain.
authors: Carmen
authors: C
authors: Hernández-Marqués
authors: Alvaro
authors: A
authors: Lassaletta
authors: Antonio
authors: A
authors: Torrelo
authors: Miguel Ángel
authors: MÁ
authors: López-Pino
authors: Javier
authors: J
authors: Álvarez-Coca
authors: Inmaculada
authors: I
authors: De Prada
authors: Ángela
authors: Á
authors: Hernández-Martín
authors: Luis
authors: L
authors: Madero
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002675:Child, Preschool; D006801:Humans; D008230:Lymphomatoid Granulomatosis / Q000188:drug therapy*; D008297:Male; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab